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ABSTRACT 
Objective: The main aim of this study was to formulate, develop and optimized a duloxetine hydrochloride (dlx-hcl) loaded mucoadhesive 
microemulsion intended for intranasal administration.  
Methods: Established on solubility studies capmul mcm, transcutol-p, labrasol were used as oil, co-surfactant and surfactant respectively. The 
optimized mucoadhesive microemulsion prepared using water titration method was further characterized for particle size, polydispersity index, 
zeta potential and conductivity measurements followed by drug content, nasal cilio toxicity and biochemical estimation of the selected formulation. 
Results: All physicochemical parameters conducted, proved that dlx-hcl microemulsion was appropriate for nasal delivery. Chitosan, used as 
mucoadhesive polymer demonstrated enhanced retention time of the microemulsion in nasal mucosa with no signs of toxicity and epithelial 
damage. The particle size and zeta potential were found to be of 200 nm and-15 mV respectively considering the formulation safe for nasal delivery.  
Conclusion: This formulation strategy can be used as an effective targeting technique for the drugs having low bioavailability and poor brain 
penetration along with an effective method for the treatment long-term disease like depression. 
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Treatment involving site-specific delivery to the central nervous 
system along with prolonged presence and sustain release of a drug 
to attain steady-state levels is regarded as an ideal effective 
psychotherapy. Major obstacles to this pathway include the blood-
brain barrier (bbb) prohibiting the entry of the drug into the brain 
[1, 2]. Intranasal delivery has become prominent as an alternative to 
invasive delivery systems in order to bypass the bbb and facilitate 
targeted therapeutic delivery. This delivery system utilizes olfactory 
and trigeminal nerve pathways [3]. The nasal route possesses 
advantages of rapid absorption of the drug, higher bioavailability 
allowing lower doses, faster onset of action [4, 5]. Nasal route 
protects drugs and biomolecules from susceptible enzymatic or 
acidic degradation, can deliver drugs directly to the brain via 
olfactory lobe and eliminate first pass metabolism [6]. Though usage 
of the nasal route in human medicine has been mostly limited to 
locally acting agents, in recent years a few systemically acting nasal 
drug products have been commercialized for menopausal 
symptoms, pain control, endometriosis and migraine headache [7]. 
Microemulsions (MEs) as colloidal carriers within size range are 
clear, optically isotropic and thermodynamically stable systems 
consisting of oil, water and surfactants with/or a co-surfactant [8]. 
Additionally, incorporation of a mucoadhesive agent in the 
microemulsion increases the nasal residence time, overcoming the 
mucociliary clearance (mcc) and enhancing bioavailability [9]. 
Microemulsion-based delivery systems hold numerous characteristics 
like thermodynamic stability, increased drug loading, enhanced 
penetration through the biological membranes, increased bioavailability 
and less inter and intra-individual variability in drug pharmacokinetics 
making them suitable for intranasal drug delivery [10, 11]. 
Microemulsions have very low surface tension and small droplet size 
which results in high absorption and permeation and can cross the 
blood-brain barrier due to their stable nature [12, 13]. 
Constraints of nasal administration include natural defence 
mechanism: nasal mucociliary clearance. Therefore, it is requisite for 
localization of the formulation on the mucosal layer of nasal cavity for 
enhanced drug absorption along with optimum retention. The 
inclusion of a well-designed mucoadhesive agent to microemulsion 
can intercept rapid nasal clearance of formulation [14, 15]. Duloxetine 
hydrochloride (dlx-hcl){(þ)-(S)-N-methyl-g-(1-naphthalenyloxy)-2-
thiophene propanamine hydrochloride} is a potent, balanced dual 
reuptake inhibitor of both serotonin and norepinephrine (snri) [16] 
recommended for maintenance treatment of the major depressive 
disorder. It undergoes hepatic first-pass metabolism, exhibits 
average oral bioavailability of 50% (systemic), is acid labile at 
gastric pH (pH 1-2) and has a low cerebrospinal fluid concentration 
on oral administration [17, 18].  
Effective treatment using antidepressants relies upon carrier 
systems exploiting approaches for drug delivery to the brain with a 
continued prolonged presence in the brain [19]. This study was 
aimed at developing a stable mucoadhesive dlx-hcl microemulsion 
for intranasal administration to improve the bioavailability of this 
drug and provide high drug brain levels along with formulation and 
characterization of dlx-hcl microemulsion in order to explore the 
feasibility of this route of administration.  
MATERIALS AND METHODS 
Materials 
Drugs and reagent: Duloxetine hydrochloride was gifted by 
Shodhana Laboratories Limited Laboratories (Hyderabad, India). 
Capmul mcm was obtained as a gift sample from Abitec Corporation 
(Janesville, United States), labrafac, labrafil 1944, labrafil 2125, 
transcutol p, labrasol, cremphore, were received as gift sample by 
Gattefosse Asia Ltd. (Mumbai, India) pluronic F-127, Pluronic F-68 
and PEG 300, PEG 400, thiobarbituric acid were purchased from 
Sigma Aldrich Chemical private Ltd, Bangalore, India. Tween 80, 
span 80, oleic acid, potassium dihydrogen phosphate, methanol and 
propylene glycol were obtained from S. D Fine Chemicals, Mumbai, 
India. Sodium chloride and Copper sulphate were obtained from 
Loba Chemie, Mumbai, India. All other ingredients used in the study 
were of analytical grade. 
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The solubility of duloxetine hydrochloride in different oils (labrafil M 
1944, labrafil M 2125, capmul mcm) surfactants (tween 80, labrasol, 
span 80) and co-surfactants (transcutol P, PEG 300, PEG 400, 
chemophore RH 40) were determined. The drug was added in excess to 
the excipients in a tightly closed eppendorf tube and was mixed 
thoroughly using vortex mixture. The dispersions were kept at 37 °C 
under agitation in water bath shaker for 72 h for equilibration. After 72 h 
of equilibration, they were centrifuged at 3000 revolutions per minute 
(rpm) for 15 min and the supernatant was then filtered and diluted with 
an appropriate solvent (methanol) for analysis. The analysis was done 
using uv spectroscopy at λmax of 230 nm [20]. 
Pseudoternary phase diagram 
The pseudoternary phase diagram of oil, surfactant, co-surfactant 
and water were constructed using a water titration method. The 
surfactant was blended with co-surfactant in fixed weight ratios 
(1:1, 2:1) of labrasol and transcutol p. Different combinations of oil 
and smix were made so that the maximum ratios were covered in 
order to precisely delineate the boundaries of phases formed in the 
phase diagrams. For each phase diagram, the ratio of oil to the smix 
was varied as 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9 (w/w). Phase 
diagram was constructed using Triplot software version 4.1.2. The 
mixture of oil and smix 
Thermodynamic stability studies 
at certain weight ratios were diluted with 
water dropwise under moderate stirring with a magnetic stirrer. 
After 24h of stirring, the mixtures were assessed visually and 
determined as being a clear and transparent microemulsion. 
The selected formulation was assessed for thermodynamic stability 
by means of visual clarity and phase separation by applying stress 
tests, including centrifugation and freeze-thaw cycles. 
Heating cooling cycle: Six cycles at refrigerator temperatures 
between 4°C and 45°C with storage for not less than 48 h were 
conducted, and the formulation examined for stability.  
Centrifugation test: Formulations were centrifuged at 3500 rpm for 
30 min and observed for phase separation. 
Freeze-thaw cycle: Thee freeze-thaw cycles were performed at 
between-21 and+25°C, for not less than 48 h at each temperature. 
Optimization of mucoadhesive and gelling excipients 
Various mucoadhesive and gelling excipients were screened to ascertain 
thermoresponsive behaviour of gelling and mucoadhesive excipients. 
Pluronic F127 and pluronic F68 were screened as gelling agents while 
chitosan and carbopol 934 P were screened as mucoadhesive agents. 
Thermoreversible gels of pluronic F127 and pluronic F68 were prepared 
using a cold method by dissolving the pluronic in distilled water and 
phosphate buffer (pH 6.7 and 7.4), at 4 °C. The solution was kept at 4 °C 
until clear and then gradually increased from 15 to 40 °C to visually 
assess its gelling behavior. Similarly, dispersions of the mucoadhesive 
agent in various concentrations were prepared, weighed, soaked in 
water and kept aside overnight at room temperatures to visually 
examine its gelling behavior.  
Preparation of formulation 
Dlx-hcl microemulsion (ME) was prepared by the water titration 
method. The calculated amount of drug was added to the oily phase 
of ME and magnetically stirred until dissolved, followed by addition 
of surfactant–cosurfactant (smix) mixture to produce a clear mixture. 
Mucoadhesive and gelling excipients were dissolved in the aqueous 
phase and kept at 4 °C to obtain a clear solution. The final drug–oil–
smix
Preparation of drug solution 
 mixture was then titrated with the aqueous phase to obtain 
mucoadhesive microemulsion and stored at refrigerated 
temperature (4 °C) for further studies. Entrapped bubbles were 
removed by placing the gels in vacuum desiccators. 
The dlx-hcl solution meant for comparative evaluation of ME-based 
systems was prepared by dissolving dlx-hcl (50 mg) in 10 ml of 
methanol resulting in a solution of 5 mg/ml. 
Characterization of formulation 
Microemulsion  
Particle size analysis  
Particle sizes of the formulations were evaluated using zetasizer; it 
was equipped with He-Ne laser source operating at a wavelength of 
633 nm. Viscosity was kept constant, with a material refractive index 
of 1.330. 1 ml of sample was taken into a cuvette and placed in the 
instrument for sample analysis.  
Zeta potential 
The measurement of zeta potential has become completely 
connected with the characterization of colloidal dispersions as this 
parameter is highly useful for the assessment of the physical 
stability of colloidal dispersions. Zeta potential was measured by 
using Beckman Coulter Delsa™ nano. 
Viscosity 
The viscosity of samples was measured at 37°C* the help of 
rotational viscometer. The viscosity and shear stress was recorded 
by varying the shear rate [21]. 
Conductivity measurements 
The conductivity of the selected formulations was done to observe 
the type of microemulsion formed. The conductivity of the 
formulations was analysed with a conductivity meter, using 
conductivity cells with a cell constant of 1.0 consisting of two 
platinum plates separated by desired distance and liquid placed 
between the platinum plates acting as a conductor. 
Thermoreversible microemulsion 
Sol-gel transition temperature and gelling time 
For in situ gel forming systems, the sol-gel transition temperature 
and time should be determined. Gelling time is the time required for 
first detection of gelation of in situ gelling system. Thermosensitive 
in situ gel should be checked for in situ gelling at body temperature. 
Drug content 
The accurately weighed amount of prepared gel was taken into a 10 
ml volumetric flask and dissolved in methanol. Suitable dilution was 
made and absorbance was checked at 230 nm in triplicate to 
determine the actual drug concentration in the formulation, using uv 
spectrophotometer. 
Entrapment efficiency 
Entrapment efficiency of mucoadhesive microemulsion was 
determined by the centrifugation method. Mucoadhesive micro-
emulsion (containing an equivalent to 50 mg of drug) was centrifuged 
at 20000 rpm for 1 h in a refrigerated centrifuge to collect the 
supernatant liquid. The collected liquid was filtered to measure the 
free drug concentration after suitable dilution with methanol. The 
absorbance was measured at 230 nm in a uv spectrophotometer to 
calculate the entrapment efficiency using the following formula:  
 
Entrapment efficiency % =  
Intial amount of durg in ME − Free drug
Intial amount of durg in ME
×  100  
 
PH  
The pH of the prepared in-situ gels was determined to evaluate 
possible irritation effects on the mucosa. The pH of the gel was 
measured at room temperature by directly immersing the pH 
electrode into the samples [22]. 
Rheological studies 
The gelled systems were evaluated for their rheological behaviour 
using Anton Paar Rheometer (Rheo QC), a cup and bob viscometer. 
The viscosity was determined at various shear rates by subjecting 
the gel to different torque values.  
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Mucoadhesion strength 
The mucoadhesive strength of formulations under investigation was 
evaluated by measuring the force required to detach the formulation 
from a mucin disc using Texture AnalyzerTM 
In vitro drug release 
(Stable Micro Systems 
TA-XT. plus Texture Analyzer Godalming, U. K. Mucin discs were 
prepared by compression of a known weight of mucin (250 mg) 
using a hydraulic press with a diameter of 20 mm. Prior to 
mucoadhesion testing, the mucin disc was hydrated by submersion 
in 5% solution of mucin for 30s. The excess surface liquid was 
removed by gentle blotting and they were attached to the lower end 
of the probe. The in-situ gels were packed into the lower platform of 
the texture analyzer. The probe holding the mucin disc was lowered 
on to the surface of the gel with a constant speed of 0.5 mm/sec and 
a contact force of 10g was applied. After keeping in contact surfaces 
for 120s, the probe was then moved vertically upward at a constant 
speed of 0.1 mm/sec. Maximum detachment force was obtained 
from the force-distance graph. From the force-distance plot, the area 
under the curve was calculated as mucoadhesion. The tests were 
conducted at 37 °C and each experiment was carried out in 
triplicate. 
To determine the release behaviour of the drug from the 
thermoreversible formulation, the in vitro release experiment was 
carried out using Franz diffusion cell including a donor chamber and 
an acceptor compartment. A dialysis membrane (MWCO 8000–
14000) with a constant contact area of 3.14 cm2
Ex vivo drug permeation studies 
 was fixed between 
the donor and receptor chamber. 1 ml of the formulation was added 
to the donor chamber. The receptor compartment was filled with 30 
ml of mixture medium of phosphate buffer (pH 6.4). The receptor 
solution was subjected to magnetic stirring at 200 RPM and kept at 
37 °C in order to mimic in vivo conditions. At predetermined time 
intervals such as 0 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h and 
24 h, 1 ml of receptor solution was withdrawn and 1 ml of blank 
receptor solution was added to maintain a constant volume. The 
samples were centrifuged at 10,000 rpm for 20 min and the 
supernatant was further diluted with methanol for the analysis of 
dlx-hcl by uv [23]. 
CR (%)  =
Cumulative release amount of drug
Total amount of drug in formulation
 
The ex-vivo diffusion study was performed using goat nasal mucosa, 
collected from a slaughterhouse. The nasal conchae was collected in 
phosphate buffer pH 6.4 and washed three times with phosphate 
buffer pH6.4. The extraneous tissues were removed with a surgical 
blade so as to separate out the mucosa. The prepared nasal mucosa 
was mounted on a Franz diffusion cell with the dermal side facing 
towards the receptor compartment. Stabilization was performed by 
stirring the receiving medium with a magnetic stirrer for 30 min in 
phosphate buffer pH 6.4. After stabilization, phosphate buffer was 
replaced with fresh media (phosphate buffer pH 6.4) and ex-vivo 
diffusion study was performed at a temperature maintained at 37 
°C±0.5. 1 ml formulation was placed on the donor side of diffusion 
cell (area =3.14 cm2
Nasal ciliotoxicity studies 
). 1 ml of sample was withdrawn at time 
intervals of 0 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h and 24 h 
and replaced with an equal volume of the phosphate buffer pH 6.4 
and assayed. Graph was plotted between % cumulative drugs 
released versus time. Slopes of the linear portion of the graph were 
used to calculate the permeation flux. 
Nasal mucosa of sheep was collected from the slaughterhouse in 
saline phosphate buffer (pH 6.4). The membrane was placed in 10% 
formalin solution to stabilize the nasal membrane. Four pieces of 
sheep nasal mucosa (P1, P2, P3 and P4) of identical thickness were 
taken and mounted on the glass slide. P1 was treated with 0.5 ml of 
phosphate buffer pH 6.4 (negative control), P2 treated with 0.5 ml of 
isopropyl alcohol (positive control), P3 and P4 were treated with 
formulations selected from the ex vivo studies. The mucosa was 
subjected to histological studies to evaluate the nasal ciliotoxicity of 
the formulations. The specimens were visualised though 
photomicrograph at 100 x magnification [24]. 
Pharmacodynamic studies 
Animals: Female wistar rats bred in Central Animal House facility of 
Panjab University, Chandigarh, and weighing 140-270 kg were used. 
The animals were housed under standard light/dark cycle with food 
and water provided ad libitum. Animals were acclimatized to 
laboratory condition before the test. The experiments were 
performed between 9.00 to 17.00 h. The experimental protocol was 
approved by the Institutional Ethics Committee of Institute 
(IAEC/589). Rats were weighed and divided into groups as follows:  
• The first group (N) of six animals comprised of naïve control rats 
which were neither exposed to stressors nor given any treatment. 
• Second group (P) comprised of positive control rats which were not 
given any treatment; however, they were exposed to stress conditions. 
• The third group (F1) comprised of rats which were given 
intranasal formulation F1 
• The fourth group (F2) comprised of rats administered with 
intranasal formulation F2 
• The fifth group (FD) comprised of rats which were given a free 
drug suspension, orally. 
Evaluation and comparison of the antidepressant effect of the 
developed in situ gelling microemulsions were performed using 
chronic unpredictable mild stress (cums) model of depression [25]. 
Locomotor activity test 
The locomotor activity in test rats was analyzed using Actophotometer 
which recorded (digital) movements of the animal inside the test 
chamber. This test provides an index of basal locomotor activity in a 
familiar environment. The rats were placed individually inside the 
chamber of actophotometer for 10 min. Average locomotor scores of 
various groups were compared with each other [26]. 
Sucrose preference test 
The sucrose preference test was employed herein to determine 
anhedonia, one of the core symptoms of major depression in humans. 
This test was performed at the end of 3 w of cums exposure. Briefly, 
before the test mice were trained to adapt to a sucrose solution (1% 
w/v): two bottles of sucrose solution were placed in each cage for 24 h, 
and then 1 bottle of sucrose solution was replaced with water for 24 h. 
After adaption, the rats were deprived of food and water for 24 h. 
Sucrose preference test was conducted by placing a bottle containing 
100 ml of water and another bottle containing 1% sucrose solution in 
the animal cages for subsequent 24 h period. The volumes consumed 
from each of these bottles were recorded and the sucrose preference 




(sucrose consumption + water consumption)
 x 100 
 
Forced swim test 
Rats were individually forced to swim inside a rectangular glass jar 
(25 X 12 X 25 cm3
Biochemical estimation  
) containing 15 cm of water maintained at 23-25 
°C. After the initial 2-3 min of vigorous activity, the animals showed 
a period of immobility by floating with minimum movements. The 
animal was considered to be in an immobile state when it remains 
floating passively in the water in a slightly hunched but upright 
position with its nose above the water surface. The total immobility 
period of 4 min after 2 min of habituation was recorded with the 
help of a stopwatch and averages of immobility time for various 
groups were compared using a bar graph [28]. 
Preparation of tissue homogenate  
At the end of 27th d, the rats were sacrificed by cervical dislocation. 
Brains of the animals were isolated and rinsed in ice-cold phosphate 
buffer saline (pH6.4). Hippocampus regions of the brain were isolated 
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and homogenized in phosphate buffer saline (pH6.4) to make a 10% 
homogenate. The 10% homogenate was then centrifuged at 10,000 rpm 
at 4 °C for 10 min and supernatants were collected from the 
hippocampus brain homogenate (hbh) and used for various biochemical 
estimations. 
Collection and preparation of plasma samples  
Anaesthetized mouse was held in the hand with its head pointing 
down. The tip of a fine capillary was inserted into the corner of the 
eye socket underneath the eyeball, directing the tip at 45-degree 
angle toward the middle of the eye socket. The capillary was rotated 
between fingers during the forward passage. Gentle downward 
pressure was applied and then released until the vein was ruptured 
and blood entered the capillary and was collected suitably. 
Estimation of protein  
The protein content was measured by biuret method using bovine 
serum albumin (bsa) as standard [29]. 0.1 ml of hbh, 2.9 ml of 
sodium chloride, 3 ml of working buiret reagent were mixed 
together. (Biuret reagent was prepared by mixing 4.5 g of sodium 
potassium tartrate in 40 ml of 2.0 N NaOH with 1.5 g copper 
sulphate. To this solution, potassium iodide was added and total 
volume was made upto 100 ml with 0.2 N of NaOH). This mixture 
was kept at room temperature for 10 min and its absorbance was 
measured at 540 nm. 
Estimation of reduced glutathione  
1 ml of hbh was precipitated with 1 ml of 4% sulfosalicylic acid and 
then these samples were incubated at 4 °C for 1 h. The samples were 
centrifuged at 1,200 × g for 15 min at 4 °C. To 1 ml of this 
supernatant, 2.7 ml of phosphate buffer (0.1 M, pH 8) and 0.2 ml of 
0.01 M 5,5-dithiobis (2-nitrobenzoic acid) (dtnb) (4 mg/ml) to a 
total volume of 3 ml were added. The yellow colour developed was 
read immediately at 412 nm uv-vis spectrophotometer. Results were 
calculated using molar extinction coefficient of chomophore (1.36 × 
104 M–1 cm–1
Estimation of lipid peroxidation 
) and expressed as nanomoles of reduced glutathione 
per milligram protein [30]. 
The quantitative measurement of lipid peroxidation was performed 
according to the method of Wills [31]. The amount of malondialdehyde 
(mda), a measure of lipid peroxidation, was measured by reaction with 
thiobarbituric acid at 532 nm using uv spectrophotometer. The values 
were calculated using molar extinction coefficient of chomophore (1.56 × 
105 M–1 cm–1) and expressed as a percentage of the control group.  
Statistical analysis 
The statistical significance of the results obtained from the release 
study was analyzed by one way ANOVA using SPSS (Version 17.0) 
software. A difference below the probability level of 0.05 (95% 
confidence interval) was considered statistically significant. 
Statement of human and animal rights 
This article does not contain any studies with human subjects performed 
by any of the authors; all institutional and national guidelines for the care 
and use of laboratory animals were followed. The experimental protocol 
was approved by the Institutional Animal Ethical Committee (IAEC) 
constituted under CPCSEA (45/GO/ReBI/S/99/CPCSEA). 
RESULTS AND DISCUSSION 
Solubility studies 
The solubility of duloxetine hcl in various oils, surfactants and 
cosurfactants were measured. Each experiment was performed in 
triplicate and averages of solubility in various excipients were 
represented graphically in fig. 1. Duloxetine showed maximum solubility 
in capmul mcm as compared to its solubility in other oils, while labrasol 
and transcutol p had shown higher drug solubility in comparison with 
other surfactants and cosurfactants respectively which were used in the 
solubility studies and hence, were used for further studies. 
 
 
Fig. 1: Solubility data of dlx-hcl in various excipients, (mean±SD, N=3) 
 
Pseudoternary phase diagram 
Two pseudoternary phase diagrams (1:1and 2:1) were constructed 
using capmul mcm as oily phase and labrasol as surfactant and 
transcutol p as cosurfactant fig. 2 (A and B). The microemulsions 
were selected from the o/w microemulsion region of pseudoternary 
phase diagrams which were subjected to thermodynamic stability 
studies including heating-cooling cycle, centrifugation testing and 
freeze-thaw cycle. The microemulsions which passed these test were 
selected for further characterization. 
 
 
Fig. 2: Pseudo-ternary phase diagram with different Smix ratio i.e., (A) 1:1 and (B) 2:1. (N=3) 
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Preparation of formulation 
Intranasal thermoreversible gelling microemulsion formulations were 
prepared using chitosan as controlled release, mucoadhesive polymer 
and absorption enhancer and PF127 as a gelling agent. ME 1, ME 2, ME 
3 formulations were successfully prepared with variation in the 
concentration of PF127 ranging from 20-23%. Prepared 
thermoreversible gelling microemulsion formulations were evaluated 
for physical properties like particle size,zeta potential, viscosity, 
conductivity, sol-gel transition temperature and gelling time, drug 
content, entrapment efficiency, pH, mucoadhesion, in vitro release 
studies, ex vivo permeation, pharmacodynamic studies. 
 
Table 1: Compositions of various intranasal duloxetine hydrochloride thermoreversible microemulsions 
S. No. Batch No. Capmul mcm (%) Labrasol: Transcutol P 
smix
Water 
 (%) (%) 
Pluronic F127 (%) Chitosan 
(%) 
1 ME 1 5 50(2:1) 45 20 0.5 
2 ME 2 15 50(2:1) 35 20 0.5 
3 ME 3 15 50(2:1) 35 23 0.5 
Smix:  
 
Characterization of formulation 
Surfactant mix, Capmul mcm: Capmul medium chain mono-diglyceride (mean±SD, N=3) 
The average diameter of particles in the selected formulation 
was in the range of 100 nm to 190 nm. The zeta potential of the 
microemulsion formulation was found to be in the range of-
35.45 to-55.32 mV. These negative zeta potential values indicate 
stability of the microemulsion due to its double-layer repulsion 
between droplets. The conductivity measurements were in the 
range of 0.105-0.128 concluding that the formulations were of 
o/w type. 
 
Table 2: In situ gelling time and gelling temperature for formulation ME1, ME2 and ME3 
Formulations Mean gelling time±SD* Mean gelling temperature±SD* 
ME 1 5.67±0.51 28 °C±0.34 
ME 2 6.33±0.31 29 °C±0.23 
ME 3 6.89±0.72 32 °C±0.43 
ME: Microemulsion, *(mean±SD, N=3) 
 
Table 2 depicted the in situ gelling time and gelling temperatures of 
microemulsion formulations. Upon administration, the formulation 
undergoes rapid sol to gel transition by ionic gelation. Gellling 
temperatures ranging from 25 °C to 37 °C have been considered to 
be suitable for thermoreversible formulations. If lower than 25 °C, a 
gel might be formed at room temperature leading to difficulty in 
manufacturing and administering whereas, if the gelation 
temperature is higher than 37 °C, the formulation might exist in its 
liquid state in the nasal cavity body temperature of 34 °C, resulting 
in its nasal clearance at an early stage [32]. Accordingly, 
formulations suitable for intranasal delivery were selected. 
Drug content of formulations was found to be in the range of 
98.98±1.40% to 99.75±0.58%., of the theoretical value (10 mg/ml). 
The pH of the microemulsion formulations was found to be in the 
range 5.9 to 6.4 i.e., closer to neutral pH range of the nasal cavity 
indicating no irritation to the nasal mucosa. The viscosity of the 
prepared formulation was found to be in the range of 25.7±1.6 cp to 
55.4±2.3 cp. Rheological study of in-situ gel formulations at 37OC 
showed non-newtonian flow whereas at 4OC formulations showed 
Newtonian flow due to the presence of pluronics, a non-ionic 
polypropylene oxide triblock copolymer which aggregates into 
micelles at 37O C. When administered intranasally, the viscosity of 
the formulation was increased, aiding dispersion in the nasal cavity. 
Further, mucoadhesion force was measured to showcase a range of 
0.259 N to 0.263N. The developed dlx-hcl thermoreversible in situ 
gel, therefore, would be retained in the nasal cavity for prolonged 
intervals with reduced expectancy to leakage and inconvenience. 
In vitro drug release 
In vitro release studies were carried out on Franz-diffusion cell using 
cellophane membranes as a barrier of the selected formulations i.e. 
ME1, ME2, and ME3. The cumulative percentage drug release at 
different time intervals of different formulations are shown in fig. 3. 
Data obtained from in vitro release experiments depicted that drug 




Fig. 3: Comparison of cumulative percentage drug release profiles, (mean±SD, N=3) 
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Ex vivo drug permeation 
The study depicted release potential of the gel, the pattern of drug 
release through in-situ gels were explained by Higuchi model which 
clearly represents controlled drug delivery in fig. 4. The selected 
formulation had shown significant release from the nasal mucosa 
with sustained effect. Higher flux value found for formulations may 
be attributed to the presence of chitosan. 
 
 
Fig. 4: Permeation of various formulations though nasal mucosa, (mean±SD, N=3) 
 
Nasal ciliotoxicity studies 
The chemicals and solubility enhancers used in the formulation may 
cause harm, especially in cases of chronic application, as many of 
them are irritant in nature. The acceptance criteria for the selection 
of the oil, surfactant and other excipients, not only depends on its 
ability to enhance solubility and absorption but also upon its overall 
safety profile on both local and systemic effect. Thus nasal mucosa 
toxicity was evaluated to determine any toxicity caused by the 
excipients used in the formulation. The intranasal microemulsion 
treated nasal mucosa showed no signs of vascular congestion and 
sub-epithelial edema, necrosis or abnormal histopathologic changes. 
It also showcased negligible irritation to the nasal mucosa, implying 
this formulation to be of excellent nasal tolerance. The results as 
shown in 
 
fig. 5(A, B and C) revealed that the developed intranasal 
formulation was non-ciliotoxic and suitable for nasal application 
whereas, fig. 5(D) revealed severe alterations on the mucosal layer 
upon treatment with 1% v/v isopropyl alcohol. 
 
Fig. 5: Histopathology of (A) Formulation F1 (B) Formulation F2 (C) Nasal membrane treated with phosphate buffer (D) Nasal membrane 
treated with isopropyl alcohol, (N=3) 
 
Pharmacodynamic studies 
Behavioural characteristics of the animal models and humans are 
impaired in chronic stress. The present study aimed to evaluate and 
compare the protective effect of dlx-hcl intranasal formulation in 
comparison to the free drug suspension given by oral route, as 
prescribed in depression. Microemulsion ME1 and ME2 mentioned 
earlier in table 1 were administered intranasally as formulation F1 
and F2 respectively. Also, oral suspension, FD of the free drug was 
administered orally. 
Locomotor activity 
In order to detect the association of neurological functions with changes 
in motor activity, the locomotor activity of rats was tested by digital 
actophotometer. The locomotor activity of cums control group was 
significantly decreased after 21 d of stress in comparison to the naive 
group of animals. There was a significant (p<0.05) decrease in the 
ambulations of the stress-induced mice compared to the naive group. 
Locomotor activity of the treated group was restored upon with dlx-hcl. 
Formulation F1 and F2 were given intranasally and oral suspension, FD 
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of the free drug was administered orally. The intranasal formulation 
exhibited an enhanced effect which was 50% more in comparison to the 
orally administered free drug, shown in fig. 6(A). This implies that the 
intranasal formulations were far more effective in comparison to the oral 
drug suspension.  
Sucrose preference test 
The sucrose preference test was employed herein to determine 
anhedonia, the inability to gain pleasure from normally pleasurable 
experiences, which is one of the core symptoms of depression. A 
significant difference in sucrose preference was observed in fig. 6(B) 
between naive group and control animals (81% in the naive group 
and 39% in control group sucrose was consumed). Moreover, 
groups treated intranasally with F1and F2 formulations showed a 
significantly increased effectiveness with F2 proving to be 55% 
more efficient than the oral formulation.  
Force swim test 
When forced to swim in the confined space, rats after an initial 
phase of vigorous activity, cease to struggle, surrendering 
themselves to the experimental conditions, which showed their 
helplessness or despair behaviour. This reflects the lowered mood in 
laboratory animals and could be used for screening of the 
antidepressant agents [33]. The immobility in this test reflects the 
development of despair behaviour which disengaged the animal 
from active forms of coping up with stressful stimuli, and this 
behaviour is sensitive to antidepressants.  
In animals exposed to cums, there was a significant (p<0.05) 
increase in the immobility time as compared to the naive group. 
Animals treated with intranasal formulation F1 and F2 as well as 
oral marketed formulation, when forced to swim, showed reduction 
in the immobility time as compared to control animals whereas, 
formulation F2 completely decreased the immobility time of the rats 
and the results were similar to those observed for naïve animals 
with 60% enhanced effectiveness as compared to the oral free drug 
suspension as depicted in fig. 6(C). This inferred the intranasal 
formulations, effectual in comparison to the oral free drug 
suspension. 
Biochemical estimations 
Reduced glutathione  
Reduced glutathione levels are significantly (p<0.05) decreased in 
the hbh of stress-induced mice by 90% compared to unstressed 
mice. Formulation F1, F2 given by intranasal route and oral free 
drug suspension administered for 21 successive days, significantly 
(p<0.05) increased reduced glutathione levels in unstressed rats as 
compared to the control rats. As seen in fig. 6(D), Formulation F1 
and F2 showed significant (p<0.05) increase in the glutathione levels 
as compared to oral one, suggesting restoration of reduced 
glutathione levels on treatment with dlx-hcl given intranasally. 
Specifically, the F2 intranasal formulation demonstrated a 40% 
enhanced treatment with respect to the oral suspension of free drug. 
Lipid peroxidation 
In the animals exposed to chonic unpredictable mild stress, there 
was a significant (p<0.05) increase in the hippocampal mda levels 
compared to animals in the naïve group. In the animals treated with 
intranasal formulations of dlx-hcl, F1 and F2 expressed reduction in 
the lipid peroxidation levels as demonstrated in fig. 6(E). In 
comparison to the oral free drug suspension, lipid peroxidation was 




Fig. 6: Effect of intranasal formulation (F1 and F2), oral formulation (FD) on (A) locomotor score (B) sucrose preference (C) immobility 
time in the FST (D) reduced glutathione levels in the hippocampal region (E) lipid peroxidation in the hippocampal region, of stress-
induced rats, (mean±SD, N=3) 
 
CONCLUSION 
The conclusion derived from this research demonstrated that the 
thermoreversible microemulsion for intranasal delivery can be 
employed to improve drug brain levels and increase dlx-hcl 
bioavailability. A formulation containing 15% capmul mcm 50% of 
2:1 Smix (labrasol: transcutol p), and water along with 20% pluronic 
F127 and 0.5% of chitosan showed better results in the treatment of 
depression as compared to oral free drug suspension of duloxetine 
in rats. It also demonstrated sustained release, enhanced in vitro 
permeability with no evidence of nasal ciliotoxicity. Therefore, 
enhanced rate and extent of brain permeability following intranasal 
administration may be favorable in decreasing the dose along with 
the frequency of dosing. Hence this formulation strategy can be used 
as an effective targeting technique for the drugs having low 
bioavailability and poor brain penetration. 
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